MabVax Therapeutics Holdings, Inc. is a clinical stage oncology drug development company focused on the development of human antibody-based products and vaccines to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines.

•MabVax is preparing to enter two Phase 1 clinical trials of HuMab 5B1 – one for the diagnosis, and the other for the treatment, of metastatic pancreatic cancer in late 2015. > Read more about HuMab 5B1

•MabVax has the exclusive license to therapeutic vaccines from Memorial Sloan Kettering Cancer Center. > Read more about our collaboration

•MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma that will be ready for Phase II clinical trial later this year. > Read more about our current clinical trials 

>Read More about MabVax Therapeutics


July 31, 2015
MabVax Releases 2015 Shareholder Letter  
Read More >

July 1, 2015
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds  
Read More >

June 1-3, 2015
MabVax to present at LD Micro Conference.
Read More >

April 7, 2015
MabVax Therapeutics Appoints Tom Varvaro to its Board of Directors.
Read More >

April 6, 2015
MabVax Therapeutics Announces Closing of Financing. 
Read More>

HuMab 5B1 Program 

MabVax's HuMab 5B1 antibody has demonstrated high specificity, affinity, and lack of cross re-activity with closely related antigens. 

Phase 2 Sarcoma Study 

Our sarcoma vaccine is currently in a proof of concept randomized, double blind, multi-center Phase II clinical trial. 

Phase 2 Ovarian Study 

Our ovarian vaccine is currently in a proof of concept randomized, double blind, multi-center Phase II clinical trial. 

MabVax Video 

New video coming soon

   Sign up for Email Alerts

Be the first to get breaking news 


 Shareholder Letter: 

2015 MabVax Shareholder Letter.pdf 2015 MabVax Shareholder Letter.pdf
Size : 170.929 Kb
Type : pdf

Investor Presentation: 

MABVAX Investor Presentation 2015.pdf MABVAX Investor Presentation 2015.pdf
Size : 575.857 Kb
Type : pdf


Loading data...
MabVax Therapeutics

Contact Us: MabVax Therapeutics
 11588 Sorrento Valley Road Suite 20
San Diego, California, 92121   (858) - 259 - 9405
email: info@mabvax.com

  © 2015, MabVax Therapeutics. All Rights Reserved 
Privacy Policy     Terms of Use     Disclaimer     Sitemap